BMJ Open Gastroenterology

Associations between prior healthcare use, time to diagnosis, and clinical outcomes in inflammatory bowel disease: a nationally representative population-based cohort study

Nishani Jayasooriya ,[1,2] Sonia Saxena,[2] Jonathan Blackwell,[3] Alex Bottle ,[2] Hanna Creese,[2] Irene Petersen,[4] Richard C G Pollok ,[1,2,5] POP-IBD Collaboration

To cite: Jayasooriya N, Saxena S, Blackwell J, *et al*. Associations between prior healthcare use, time to diagnosis, and clinical outcomes in inflammatory bowel disease: a nationally representative population-based cohort study. *BMJ Open Gastroenterol* 2024;**11**:e001371. doi:10.1136/bmjgast-2024-001371

► Additional supplemental material is published online only. To view, please visit the journal online (https://doi.org/10.1136/bmjgast-2024-001371).

Received 3 February 2024
Accepted 23 April 2024

For numbered affiliations see end of article.

Correspondence to
Dr Nishani Jayasooriya; nishani.jayasooriya@nhs.net

Dr Richard C G Pollok; richard.pollok@nhs.net

ABSTRACT

Background Timely diagnosis and treatment of inflammatory bowel disease (IBD) may improve clinical outcomes.

Objective Examine associations between time to diagnosis, patterns of prior healthcare use, and clinical outcomes in IBD.

Design Using the Clinical Practice Research Datalink we identified incident cases of Crohn's disease (CD) and ulcerative colitis (UC), diagnosed between January 2003 and May 2016, with a first primary care gastrointestinal consultation during the 3-year period prior to IBD diagnosis. We used multivariable Cox regression to examine the association of primary care consultation frequency (n=1, 2, >2), annual consultation intensity, hospitalisations for gastrointestinal symptoms, and time to diagnosis with a range of key clinical outcomes following diagnosis.

Results We identified 2645 incident IBD cases (CD: 782; UC: 1863). For CD, >2 consultations were associated with intestinal surgery (adjusted HR (aHR)=2.22, 95% CI 1.45 to 3.39) and subsequent CD-related hospitalisation (aHR=1.80, 95% CI 1.29 to 2.50). For UC, >2 consultations were associated with corticosteroid dependency (aHR=1.76, 95% CI 1.28 to 2.41), immunomodulator use (aHR=1.68, 95% CI 1.24 to 2.26), UC-related hospitalisation (aHR=1.43, 95% CI 1.05 to 1.95) and colectomy (aHR=2.01, 95% CI 1.22 to 3.27). For CD, hospitalisation prior to diagnosis was associated with CD-related hospitalisation (aHR=1.30, 95% CI 1.01 to 1.68) and intestinal surgery (aHR=1.71, 95% CI 1.13 to 2.58); for UC, it was associated with immunomodulator use (aHR=1.42, 95% CI 1.11 to 1.81), UC-related hospitalisation (aHR=1.36, 95% CI 1.06 to 1.95) and colectomy (aHR=1.54, 95% CI 1.01 to 2.34). For CD, consultation intensity in the year before diagnosis was associated with CD-related hospitalisation (aHR=1.19, 95% CI 1.12 to 1.28) and intestinal surgery (aHR=1.13, 95% CI 1.03 to 1.23); for UC, it was associated with corticosteroid use (aHR=1.08, 95% CI 1.04 to 1.13), corticosteroid dependency (aHR=1.05, 95% CI 1.00 to 1.11), and UC-related hospitalisation (aHR=1.12, 95% CI 1.03 to 1.21). For CD, time to diagnosis was associated with risk of CD-related hospitalisation (aHR=1.03, 95% CI 1.01 to 1.68); for UC, it was associated with reduced risk of UC-related hospitalisation (aHR=0.83, 95% CI 0.70 to 0.98) and colectomy (aHR=0.59, 95% CI 0.43 to 0.80).

Conclusion Electronic records contain valuable information about patterns of healthcare use that can be used to expedite timely diagnosis and identify aggressive forms of IBD.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Diagnostic delay, from the point of first healthcare consultation, and increased healthcare utilisation may occur prior to inflammatory bowel disease (IBD) diagnosis, but their relationship to subsequent clinical outcomes is not yet established.

WHAT THIS STUDY ADDS

⇒ Increased primary care consultation frequency and intensity for gastrointestinal symptoms prior to diagnosis are associated with worse clinical outcomes in IBD, particularly risk of intestinal surgery.

⇒ Hospitalisation for gastrointestinal symptoms before diagnosis is also associated with an increased risk of intestinal surgery following diagnosis.

⇒ Longer time to diagnosis was associated with an increased risk of Crohn's disease-related hospitalisation.

⇒ Paradoxically, a longer time to diagnosis was associated with a milder disease course in ulcerative colitis.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Expedited diagnostic approaches are required for patients who return repeatedly with unresolved gastrointestinal symptoms.

⇒ Electronic records contain valuable information about patterns of healthcare use that can be used to prompt targeted timely referral and identification of aggressive forms of IBD.

INTRODUCTION

Inflammatory bowel disease (IBD) is a chronic relapsing and remitting gastrointestinal condition, which in its initial stages can

be challenging and time consuming to diagnose.[1 2] Timely diagnosis enables early treatment to relieve patients' symptoms and potentially reduces the risk of disease progression, hospitalisation and surgery.[3–5] However, previous studies report that patients can wait for months to several years from symptom onset before receiving a diagnosis of IBD.[1 6]

Reasons for delay in diagnosis are likely complex. Patients may be unaware of the significance of their symptoms or be embarrassed to seek medical advice. One-tenth of patients report excess gastrointestinal symptoms 5 years before their eventual diagnosis with Crohn's disease (CD) or ulcerative colitis (UC).[1] However, symptoms of IBD may often be mistaken for more prevalent benign gastrointestinal conditions, such as irritable bowel syndrome (IBS) and haemorrhoids, particularly during the early stages of disease.[7 8]

Targeted investigation can expedite diagnosis.[9] Set against this is the rising demand placed on healthcare services, which has been exacerbated in the wake of the COVID-19 pandemic. Individuals may be required to consult repeatedly before receiving a final diagnosis of IBD or, alternatively, need to access emergency hospital services.[10]

Previous studies have reported a higher than background prevalence of gastrointestinal symptoms and increased healthcare use and costs encountered in the years prior to IBD diagnosis, of which some encounters may be considered missed opportunities to diagnose, commence timely treatment and prevent disease progression.[1 11] However, the association between patterns of healthcare use in the period prior to IBD diagnosis and subsequent clinical outcomes has not previously been thoroughly evaluated. In other chronic conditions, such as heart failure and malignancy, more frequent consultation, including emergency hospital admission prior to diagnosis, is associated with worse disease-related outcomes.[12 13]

The natural progression of IBD is variable and can range from indolent to an aggressive, rapidly evolving disease behaviour. While some studies have reported an association between diagnostic delay and the risk of disease complications, others have not.[6] Most studies have relied on retrospective estimates of symptom duration before diagnosis, collected using patient questionnaires, from hospital cohorts, and are therefore subject to bias and are not representative.[6]

It is not clear which patients presenting with gastrointestinal symptoms will benefit from expedited investigation. To determine how patterns of consultation are predictive of worse IBD outcomes we designed a nationally representative population-based retrospective cohort study using linked primary care and hospital records. We aimed to examine the association between time to diagnosis, frequency/intensity of primary care and inpatient hospital episodes for gastrointestinal symptoms in the years before diagnosis, and the risk of subsequent adverse clinical outcomes in patients with IBD.

METHODS

Data source

We analysed routinely collected primary care data from electronic health records from primary care practices that contributed to the Clinical Practice Research Datalink (CPRD), one of the largest validated primary care research databases in the world.[14] It contains longitudinal, patient-level, deidentified electronic health records of 18 million patients from more than 700 general practices and is broadly representative of the UK population. The median follow-up for individuals registered in the CPRD is 9.4 years, allowing the study of long-term outcomes. We used CPRD GOLD version that contains data contributed by practices using Vision software. Primary care physicians use clinical codes to record symptoms, diagnoses, and prescriptions. Participating practices need to achieve and maintain 'up to standard' status to continue contributing to the dataset. The CPRD GOLD coding system has been extensively validated for use in IBD.[15 16] CPRD primary care records are individually linked to the Hospital Episode Statistics (HES) database, which includes data on admissions and outpatient appointments in National Health Service hospitals in England.

Case definition and cohort construction

We identified incident cases of IBD diagnosed between January 2003 and May 2016 who had their first primary care consultation record for gastrointestinal symptoms in the 3-year period prior to their IBD diagnosis. We chose this interval since we previously found most individuals with IBD first consulted for gastrointestinal symptoms within this time period prior to diagnosis.[1] All individuals required at least 4 years of follow-up from registering with their general practice before IBD diagnosis, with the first of these years free of any record of gastrointestinal symptoms (online supplemental appendices 1 and 2). We defined incident IBD cases, using a previously validated and published methodology, as individuals who had a first diagnostic Read code for either CD or UC registered with an 'up to standard' practice.[17 18] We excluded individuals if they had codes for both CD and UC, or indeterminate codes such as 'non-specific colitis'. All individuals included in the study had linkage between CPRD and HES. We identified individuals who consulted a primary care physician with their first gastrointestinal symptom(s), within the 3-year period before their IBD diagnosis, as we have previously shown a higher than background prevalence and incidence of gastrointestinal symptoms occur in this time frame and are therefore likely to be related to IBD.[1] We used previously published and validated lists of Read codes to identify gastrointestinal symptoms of IBD, including abdominal or perianal pain, diarrhoea and rectal bleeding (online supplemental appendix 1).[1] Patients were followed up from the date of IBD diagnosis until the first recorded outcome, deregistration, or death, if these occurred before that time, or the study endpoint defined as 5 years following IBD diagnosis.

Exposures

Time to IBD diagnosis, consultation frequency, consultation intensity and hospitalisation for gastrointestinal symptoms prior to IBD diagnosis were the primary exposure variables. We defined time to diagnosis as the number of months from the first recorded date of consultation for gastrointestinal symptom(s) to the date of IBD diagnosis, defined as the date of the first recorded code for an IBD diagnosis in CPRD. For consultation frequency, we allocated patients to groups according to the number of primary care consultations for gastrointestinal symptoms (1, 2, and >2) in the 3-year period before receiving a diagnosis of IBD. We examined the impact of consultation intensity, defined as consultation frequency per person in each individual year in the 3-year period prior to IBD diagnosis. Finally, we identified individuals who required hospital admission related to gastrointestinal symptoms prior to IBD diagnosis. This was defined as individuals who had a code (International Statistical Classification of Diseases and Related Health Problems, ICD-10) that included relevant gastrointestinal symptoms: abdominal pain, diarrhoea and per rectal bleeding, listed as their primary reason for admission (online supplemental appendix 1).

Outcomes

Study outcomes were oral corticosteroid use and dependency (surrogate measure of disease activity and severity), treatment escalation requiring immunomodulator use, IBD-related hospitalisation and IBD-related surgery.

We defined individuals as 'exposed to oral corticosteroid' if they had at least one prescription for corticosteroid during the study follow-up period. Second, we identified individuals with corticosteroid dependency, adapted from European Crohn's and Colitis Organisation guidelines criteria.[19] An individual was defined as 'corticosteroid-dependent' if they had either a prescription for corticosteroid that lasted longer than 3 months or required a repeat corticosteroid prescription within 3 months of stopping the previous corticosteroid course.[19 20]

Immunomodulator use was defined as the first prescription date of azathioprine, mercaptopurine or methotrexate following IBD diagnosis.

We used a previously published list of ICD-10 codes to identify individuals where IBD was the primary reason for admission following diagnosis.[21] We excluded day case activity and 'zero-day admissions', which can represent routine care such as endoscopic surveillance or administration of therapy.[21]

We used previously published Office of Population Censuses and Surveys Classification of Interventions and Procedures (OPCS) Version 4 codes to identify surgical procedures in the HES database.[21] CD surgery was subcategorised as either major intra-abdominal (intestinal) surgery or perianal surgery. Colectomy was defined as any colectomy procedure following diagnosis of UC.[17 21]

Factors associated with time to diagnosis and patterns of consultation prior to IBD diagnosis

We identified potential factors associated with time to diagnosis, primary care consultation frequency, intensity, and hospital admission for gastrointestinal symptoms prior to IBD diagnosis, based on clinical knowledge and published literature. Age, low socioeconomic status, and smoking are associated with diagnostic delay in other chronic conditions.[22 23] Younger age at diagnosis is also known to be associated with a more aggressive disease phenotype in IBD.[23] We grouped individuals according to their age at diagnosis of IBD according to the Montreal classification (<17, 17–40 and >40 years). We used a postcode-linked marker of social deprivation, the Index of Multiple Deprivation (IMD), to group patients by socioeconomic status from IMD 1 (least deprived) to 5 (most deprived).

IBS and depression have been reported to be associated with a longer time to specialist review in IBD[1] and worse outcomes.[24–26] Poor mental health has been associated with increased healthcare use in other chronic disease.[27] We identified individuals who had codes for IBS, depression, anxiety or symptoms of depression or anxiety before their index presentation with gastrointestinal symptoms.

Individuals were classed as 'smokers', 'ex-smokers' or 'non-smokers' based on codes for smoking status in the 10 years before presentation with gastrointestinal symptoms using a previously reported methodology accounting for missing data.[1 20 28] We considered the era of IBD diagnosis to account for secular change over the study period (era 1: 2003–2005; era 2: 2006–2008; era 3: 2009–2011; era 4: 2012–2016).

Statistical analysis

We used simple and multiple Cox regression analysis to calculate HRs and 95% CIs for our listed clinical outcome measures in the 5 years following diagnosis, given time to IBD diagnosis, gastrointestinal-related consultation frequency and hospital admission prior to IBD diagnosis. We also analysed the association between intensity of gastrointestinal consultations in primary care for each year in the 3 years prior to diagnosis and subsequent clinical outcomes. Within the multiple regression models, we adjusted for sex, age at diagnosis, social deprivation, smoking status, and era of diagnosis. Analysis was carried out separately for individuals diagnosed with CD and UC.

We used Kaplan-Meier analysis to present time-to-event curves of IBD-related clinical outcomes in the 5 years following diagnosis given consultation frequency in primary care for gastrointestinal symptoms. We used multiple Cox regression to examine factors that may be associated with time to diagnosis; logistic regression was used to examine factors that may be associated with gastrointestinal-related consultation frequency in primary care and hospital admission prior to diagnosis of IBD. Analyses were performed using STATA V.17 (StataCorp, College Station, Texas, USA).

Table 1 Baseline characteristics of study population

IBD status	Crohn's disease n=782	Ulcerative colitis n=1863
Gender, n (%)		
Male	390 (50)	1021 (55)
Female	392 (50)	842 (45)
Age at diagnosis (years), n (%)		
<17	86 (11)	63 (3)
17–40	380 (49)	612 (33)
>40	316 (40)	1188 (64)
Social deprivation, n (%)		
IMD 1–3	512 (65)	1311 (70)
IMD 4–5	270 (36)	552 (30)
Time to diagnosis from first gastrointestinal consultation		
Median (IQR), months	7 (2–18)	5 (2–16)
Primary care consultation frequency, n (%)		
1	264 (34)	822 (44)
2	200 (26)	533 (29)
>2	318 (41)	508 (27)
Hospitalisation for gastrointestinal symptoms before diagnosis, n (%)	339 (43)	623 (33)

IMD 1 represents the least deprived and IMD 5 the most deprived.
IBD, inflammatory bowel disease; IMD, Index of Multiple Deprivation.

RESULTS

We identified 2645 individuals with a new diagnosis of IBD between January 2003 and May 2016 who had their first gastrointestinal-related primary care consultation in the 3-year period prior to IBD diagnosis (table 1 and online supplemental appendix 2). The median time from the first consultation with gastrointestinal symptoms to diagnosis of CD was 7 months (IQR: 2–18 months) compared with 5 months (IQR: 2–16 months) for UC; 37% (n=288) and 31% (n=580) of individuals experienced gastrointestinal symptoms for more than a year before being diagnosed with CD and UC, respectively.

The median number of consultations for gastrointestinal symptoms prior to CD diagnosis was 3 (IQR: 1–3; total range: 1–17) compared with 2 (IQR: 1–3; total range: 1–15) in UC. We found 41% and 27% of individuals, who went on to be diagnosed with CD and UC, respectively, had a primary care consultation for gastrointestinal symptoms more than twice during the 3-year period prior to diagnosis. Among the whole cohort, 36% (n=962; CD=339 and UC=623) of individuals required gastrointestinal-related hospital admission prior to IBD diagnosis (online supplemental appendix 2).

Time to IBD diagnosis and clinical outcomes

Among individuals diagnosed with CD, we found that a longer time to diagnosis from first consultation for gastrointestinal symptoms was associated with increased risk of hospitalisation (adjusted HR (aHR)=1.03, 95% CI 1.01 to 1.68), but not surgery, in the 5 years following diagnosis (table 2a). Among individuals diagnosed with UC, a longer time to diagnosis was associated with a lower risk of corticosteroid use (aHR=0.87, 95% CI 0.79 to 0.97), UC-related hospitalisation (aHR=0.83, 95% CI 0.70 to 0.98) and colectomy (aHR=0.59, 95% CI 0.43 to 0.80) in the 5 years following diagnosis (table 2b).

Gastrointestinal consultations before diagnosis and clinical outcomes

Among individuals diagnosed with CD, those who presented to primary care with gastrointestinal symptoms more than twice prior to diagnosis had an increased risk of CD-related hospitalisation (aHR=1.80, 95% CI 1.29 to 2.50) and intestinal surgery (aHR=2.22, 95% CI 1.45 to 3.39) in the 5 years following diagnosis, compared with those who had only one consultation (table 2a and figure 1). Among individuals diagnosed with UC, those who presented to primary care with gastrointestinal symptoms more than twice prior to diagnosis had an increased risk of corticosteroid use (aHR=1.60, 95% CI 1.31 to 1.96), corticosteroid dependency (aHR=1.76, 95% CI 1.28 to 2.14), immunomodulator use (aHR=1.68, 95% CI 1.24 to 2.26), UC-related hospitalisation (aHR=1.43, 95% CI 1.05 to 1.95) and colectomy (aHR=2.01, 95% CI 1.22 to 3.27) compared with those who had only one consultation (table 2b and figure 2).

Consultation intensity in primary care was highest in the year prior to diagnosis and was associated with worse clinical outcomes in both CD and UC. In the year before diagnosis, 26% and 17% of individuals diagnosed with

Table 2 Association of time to diagnosis, consultation frequency and hospitalisation for gastrointestinal symptoms before diagnosis with clinical outcomes following diagnosis of (a) Crohn's disease and (b) ulcerative colitis*

(a) Crohn's disease	CS use	CS dependency	IM use	IBD hospitalisation	Intestinal surgery	Perianal surgery
	Adjusted HR (95% CI)	**Adjusted HR (95% CI)**	**Adjusted HR (95% CI)**	**Adjusted HR (95% CI)**	**Adjusted HR (95% CI)**	**Adjusted HR (95% CI)**
Consultation frequency						
1	–	–	–	–	–	–
2	0.90 (0.68 to 1.18)	1.11 (0.74 to 1.65)	1.05 (0.78 to 1.43)	1.35 (0.94 to 1.93)	1.58 (0.99 to 2.51)	1.08 (0.81 to 1.44)
≥3	1.21 (0.94 to 1.56)	1.23 (0.84 to 1.80)	1.11 (0.84 to 1.52)	**1.80 (1.29 to 2.50)**	**2.22 (1.45 to 3.39)**	1.00 (0.79 to 1.36)
Time to diagnosis	0.89 (0.78 to 1.01)	0.89 (0.73 to 1.07)	0.92 (0.80 to 1.06)	**1.03 (1.01 to 1.68)**	0.87 (0.71 to 1.06)	1.00 (0.88 to 1.15)
Prediagnosis hospital admission	0.96 (0.76 to 1.21)	1.05 (0.78 to 1.42)	0.78 (0.60 to 1.01)	1.30 (1.01 to 1.68)	**1.71 (1.13 to 2.58)**	1.19 (0.96 to 1.48)
Sex						
Female	–	–	–	–	–	–
Male	1.13 (0.55 to 0.86)	0.85 (0.62 to 1.15)	1.04 (0.83 to 1.32)	1.12 (0.87 to 1.44)	1.20 (0.86 to 1.66)	1.05 (0.84 to 1.30)
Age at IBD diagnosis (years)						
>40						
<17	**1.45 (1.00 to 2.09)**	1.20 (0.68 to 2.12)	**3.60 (2.47 to 5.24)**	**2.31 (1.51 to 3.56)**	0.71 (0.37 to 1.36)	**1.72 (1.18 to 2.51)**
17–40	**1.46 (1.16 to 1.83)**	1.26 (0.90 to 1.76)	**1.89 (1.43 to 2.49)**	1.52 (1.14 to 2.03)	1.18 (0.83 to 1.68)	1.27 (0.99 to 1.62)
Era of IBD diagnosis						
Era 1	–	–	–	–	–	–
Era 2	1.07 (0.82 to 1.42)	0.88 (0.59 to 1.29)	1.50 (0.66 to 1.41)	1.18 (0.83 to 1.69)	1.34 (0.86 to 2.08)	1.37 (0.98 to 1.92)
Era 3	0.90 (0.91 to 0.68)	0.72 (0.47 to 1.11)	2.02 (1.41 to 1.26)	1.15 (0.80 to 1.65)	1.29 (0.81 to 2.06)	**2.21 (1.58 to 3.09)**
Era 4	1.32 (0.99 to 1.77)	0.76 (0.49 to 1.18)	3.32 (2.34 to 4.74)	**2.00 (1.35 to 2.98)**	1.25 (0.76 to 2.04)	**4.54 (3.28 to 6.28)**
Smoking status*						
Never	–	–	–	–	–	–
Ex-smoker	0.85 (0.61 to 1.18)	0.90 (0.55 to 1.48)	0.91 (0.65 to 1.26)	0.60 (0.38 to 0.93)	0.96 (0.63 to 1.46)	0.94 (0.67 to 1.31)
Current	0.99 (0.75 to 1.31)	1.22 (0.82 to 1.83)	0.88 (0.65 to 1.19)	1.05 (0.75 to 1.48)	0.76 (0.50 to 1.16)	0.90 (0.67 to 1.20)
Social deprivation						
IMD 1–3	–	–	–	–	–	–
IMD 4–5	1.12 (0.91 to 1.39)	1.14 (0.83 to 1.56)	0.97 (0.76 to 1.24)	1.12 (0.86 to 1.46)	1.11 (0.80 to 1.55)	0.87 (0.69 to 1.08)

(b) Ulcerative colitis	CS use	CS dependency	IM use	IBD hospitalisation	Colectomy
	Adjusted HR (95% CI)	**Adjusted HR (95% CI)**	**Adjusted HR (95% CI)**	**Adjusted HR (95% CI)**	**Adjusted HR (95% CI)**
Consultation frequency					
1	–	–	–	–	–
2	**1.26 (1.04 to 1.60)**	1.28 (0.94 to 1.75)	1.12 (0.83 to 1.51)	1.24 (0.93 to 1.66)	0.93 (0.55 to 1.57)

Continued

Table 2 Continued

(b) Ulcerative colitis	CS use	CS dependency	IM use	IBD hospitalisation	Colectomy
≥3	**1.60 (1.31 to 1.96)**	**1.76 (1.28 to 2.41)**	**1.68 (1.24 to 2.26)**	**1.43 (1.05 to 1.95)**	**2.01 (1.22 to 3.27)**
Time to diagnosis	**0.87 (0.79 to 0.97)**	0.95 (0.81 to 1.11)	0.88 (0.76 to 1.03)	**0.83 (0.70 to 0.98)**	**0.59 (0.43 to 0.80)**
Prediagnosis hospital admission	1.18 (0.99 to 1.39)	1.04 (0.80 to 1.36)	**1.42 (1.11 to 1.81)**	**1.36 (1.06 to 1.95)**	**1.54 (1.01 to 2.34)**
Sex					
Female	–	–	–	–	–
Male	1.00 (0.85 to 1.17)	**1.37 (1.06 to 1.76)**	1.16 (0.92 to 1.48)	1.01 (0.79 to 1.29)	1.42 (0.93 to 2.16)
Age at IBD diagnosis (years)					
>40	–	–	–	–	–
<17	**1.82 (1.24 to 2.69)**	**2.38 (1.37 to 4.12)**	**3.35 (2.07 to 5.43)**	**3.40 (1.47 to 1.89)**	**2.54 (1.09 to 5.95)**
17–39	**1.34 (1.14 to 1.60)**	**1.52 (1.17 to 1.98)**	**1.83 (1.42 to 2.34)**	**1.47 (1.14 to 1.89)**	**1.81 (1.17 to 2.79)**
Era of IBD diagnosis					
Era 1	–	–	–	–	–
Era 2	1.14 (0.92 to 1.43)	1.05 (0.76 to 1.44)	1.11 (0.78 to 1.57)	0.82 (0.58 to 1.13)	0.65 (0.38 to 1.09)
Era 3	**1.35 (1.07 to 1.70)**	0.83 (0.58 to 1.20)	**1.53 (1.08 to 2.15)**	0.91 (0.66 to 1.29)	0.62 (0.35 to 1.11)
Era 4	**1.44 (1.14 to 1.83)**	0.76 (0.52 to 1.12)	**1.95 (1.36 to 2.80)**	1.15 (0.79 to 1.58)	0.85 (0.46 to 1.54)
Smoking status*					
Never	–	–	–	–	–
Ex-smoker	0.94 (0.99 to 1.54)	0.88 (0.63 to 1.23)	0.89 (0.64 to 1.22)	0.79 (0.51 to 1.03)	1.33 (0.75 to 2.34)
Current	0.97 (1.13 to 1.79)	0.59 (0.32 to 1.05)	0.81 (0.49 to 1.32)	0.78 (0.48 to 1.30)	0.89 (0.36 to 2.20)
Social deprivation					
IMD 1–3	–	–	–	–	–
IMD 4–5	1.06 (0.89 to 1.26)	0.91 (0.69 to 1.1)	0.79 (0.61 to 1.02)	1.26 (0.98 to 1.62)	0.65 (0.40 to 1.05)

Bold indicates statistical significance in adjusted model.
IMD categories 4 and 5 (most deprived) versus IMD categories 1, 2 and 3 (least deprived).
Era 1: 2003–2005, Era 2: 2006–2008, Era 3: 2009–2011, Era 4: 2012–2016.
First CS use: time to first CS prescription following diagnosis.
CS dependency: corticosteroid dependency defined as a repeat steroid prescription within 3 months of the end of a previous steroid prescription or patients with steroid prescriptions for greater than 3 consecutive months.
Hospitalisation: IBD-related hospital admission following diagnosis.
Time to diagnosis: Time from first primary care consultation for gastrointestinal symptom(s).
*See online supplemental appendix 3 for unadjusted analyses.
CS, corticosteroid; IBD, inflammatory bowel disease; IM, immunomodulator; IMD, Index of Multiple Deprivation.



Figure 1 Probability of (A) Crohn's disease (CD)-related intestinal surgery and (B) CD-related hospitalisation following diagnosis given consultation frequency for gastrointestinal symptoms prior to diagnosis.

CD and UC, respectively, consulted more than twice, compared with 4% and 2%, and 3% and 1%, in the second and third years before diagnosis, respectively.

In CD, individuals with a higher consultation intensity in the year prior to diagnosis had an increased risk of CD-related hospitalisation (aHR=1.19, 95% CI 1.12 to 1.28) and intestinal surgery (aHR=1.13, 95% CI 1.03 to 1.23) in the 5 years following diagnosis (table 3a). In UC, individuals with a higher consultation intensity in the year prior to diagnosis had an increased risk of corticosteroid use (aHR=1.08, 95% CI 1.04 to 1.13), corticosteroid dependency (aHR=1.05, 95% CI 1.00 to 1.11), and UC-related hospitalisation (aHR=1.12, 95% CI 1.03 to 1.21) (table 3b).

Hospitalisation before diagnosis and subsequent clinical outcomes

Individuals who required hospitalisation for gastrointestinal symptoms prior to CD diagnosis had an increased risk of CD-related hospitalisation (aHR=1.30, 95% CI 1.01 to 1.68) and intestinal surgery (aHR=1.71, 95% CI 1.13 to 2.58) in the 5 years following CD diagnosis, compared with individuals who had none (table 2a). Among individuals diagnosed with UC, gastrointestinal-related hospital admission prior to diagnosis was associated with an increased risk of immunomodulator use (aHR=1.42, 95% CI 1.11 to 1.81), UC-related hospitalisation (aHR=1.36, 95% CI 1.06 to 1.95) and colectomy (aHR=1.54, 95% CI 1.01 to 2.34) in the 5 years after diagnosis, compared with individuals who had none (table 2b).

Factors associated with time to diagnosis and patterns of consultation before IBD diagnosis

Females and individuals with a diagnosis of IBS or depression and/or anxiety were more likely to have a longer time to diagnosis of IBD compared with those without. Similarly, individuals with a diagnosis of IBS, depression and/or anxiety were more likely to consult more than twice with gastrointestinal symptoms compared with those who presented only once. Individuals under 17 years of age at diagnosis were more likely to consult primary care more than twice and require gastrointestinal-related hospital admission prior to diagnosis, when compared with individuals over 40 years. Smokers were 42% more likely to consult more than twice with gastrointestinal symptoms than never smokers. Individuals aged <17 and between 17 and 39 years were associated with higher consultation intensity in the year prior to diagnosis. Those living in areas of greater socioeconomic deprivation were 29% more likely to require hospitalisation for gastrointestinal symptoms prior to diagnosis when compared with individuals living in more affluent postcodes. Compared with individuals diagnosed during 2003–2005, those diagnosed in the era 2012–2016 were 61% more likely to have hospitalisation for gastrointestinal symptoms prior to IBD diagnosis (table 4).



Figure 2 Probability of (A) corticosteroid use and (B) corticosteroid dependency in ulcerative colitis (UC) following diagnosis given consultation frequency for gastrointestinal symptoms prior to diagnosis.

Table 3 Association of consultation intensity with gastrointestinal symptoms in the years before diagnosis with clinical outcomes following (a) Crohn's disease diagnosis and (b) ulcerative colitis*

(a) Crohn's disease						
Year before diagnosis	**CS use**	**CS dependency**	**IM use**	**IBD hospitalisation**	**Intestinal surgery**	**Perianal surgery**
	Adjusted HR (95% CI)	**Adjusted HR (95% CI)**	**Adjusted HR (95% CI)**	**Adjusted HR (95% CI)**	**Adjusted HR (95% CI)**	**Adjusted HR (95% CI)**
Year 1	1.03 (0.98 to 1.08)	1.01 (0.96 to 1.07)	1.00 (0.95 to 1.06)	**1.19 (1.12 to 1.28)**	**1.13 (1.03 to 1.23)**	1.05 (0.98 to 1.13)
Year 2	1.00 (0.92 to 1.09)	0.99 (0.90 to 1.09)	1.03 (0.94 to 1.12)	**1.13 (1.01 to 1.25)**	0.86 (0.71 to 1.03)	1.00 (0.90 to 1.12)
Year 3	0.96 (0.95 to 1.08)	0.99 (0.88 to 1.11)	0.90 (0.80 to 1.02)	1.10 (0.91 to 1.33)	1.25 (0.99 to 1.48)	0.98 (0.87 to 1.11)

(b) Ulcerative colitis					
Year before diagnosis	**CS use**	**CS dependency**	**IM use**	**IBD hospitalisation**	**Colectomy**
	Adjusted HR (95% CI)	**Adjusted HR (95% CI)**	**Adjusted HR (95% CI)**	**Adjusted HR (95% CI)**	**Adjusted HR (95% CI)**
Year 1	**1.08 (1.04 to 1.13)**	**1.05 (1.00 to 1.11)**	1.03 (0.98 to 1.08)	**1.12 (1.03 to 1.21)**	1.12 (0.99 to 1.26)
Year 2	1.03 (0.96 to 1.11)	1.07 (0.98 to 1.15)	1.03 (0.95 to 1.13)	1.05 (0.92 to 1.20)	0.91 (0.68 to 1.20)
Year 3	1.02 (0.93 to 1.12)	1.05 (0.96 to 1.16)	1.03 (0.93 to 1.13)	1.00 (0.81 to 1.23)	1.00 (0.73 to 1.28)

Bold indicates statistical significance in adjusted model.
IMD categories 4 and 5 (most deprived) versus IMD categories 1, 2 and 3 (least deprived).
Era 1: 2003–2005, Era 2: 2006–2008, Era 3: 2009–2011, Era 4: 2012–2016.
First CS use: time to first CS prescription following diagnosis.
CS dependency: corticosteroid dependency defined as a repeat steroid prescription within 3 months of the end of a previous steroid prescription or patients with steroid prescriptions for greater than 3 consecutive months.
Hospitalisation: IBD-related hospital admission following diagnosis.
Consultation intensity: consultation frequency per person, as a continuous variable, in each individual year over the 3-year period before diagnosis.
*See online supplemental appendix 4 for unadjusted analyses.
CS, corticosteroid; IBD, inflammatory bowel disease; IM, immunomodulator; IMD, Index of Multiple Deprivation.

Table 4 Factors associated with time to diagnosis, consultation frequency, consultation intensity and hospitalisation before diagnosis of IBD*

	Time to diagnosis	Consultation frequency	Consultation intensity	Prior GI hospitalisation
	Adjusted HR (95% CI)	**Adjusted OR (95% CI)**	**Adjusted coefficient (95% CI)**	**Adjusted OR (95% CI)**
Age				
>40	–	–	–	–
<17	0.99 (0.82 to 1.17)	**2.32 (1.40 to 2.01)**	**0.44 (0.20 to 0.67)**	**1.74 (1.21 to 2.48)**
17–39	0.99 (0.91 to 1.07)	**1.68 (1.60 to 3.38)**	**0.37 (0.25 to 0.48)**	0.95 (0.80 to 1.14)
Sex				
Male	–	–	–	–
Female	**0.89 (0.82 to 0.96)**	1.12 (0.94 to 1.33)	0.00 (–0.11 to 1.11)	0.96 (0.81 to 1.13)
Social deprivation				
IMD 1–3	–	–	–	–
IMD 4–5	1.01 (0.93 to 1.10)	1.09 (0.91 to 1.30)	0.10 (–0.02 to 0.22)	**1.29 (1.09 to 1.54)**
Smoking status*				
Never	–	–	–	–
Ex-smoker	0.91 (0.82 to 1.01)	1.06 (0.84 to 1.34)	0.03 (–0.10 to 0.25)	1.16 (0.93 to 1.46)
Current	0.93 (0.88 to 1.08)	**1.42 (1.07 to 1.88)**	**0.34 (0.16 to 0.51)**	1.23 (0.94 to 1.63)
Premorbid depression—anxiety	**0.87 (0.78 to 0.96)**	**1.28 (1.02 to 1.60)**	0.12 (–0.22 to 0.27)	1.17 (0.91 to 1.52)
Premorbid IBS	**0.66 (0.58 to 0.75)**	**1.87 (1.44 to 2.41)**	0.08 (–0.10 to 0.25)	1.18 (0.95 to 1.46)
Era of diagnosis				
Era 1	–	–	–	–
Era 2	1.06 (0.95 to 1.18)	1.04 (0.82 to 1.32)	–0.74 (–0.22 to 0.07)	**1.31 (1.04 to 1.64)**
Era 3	1.01 (0.91 to 1.13)	1.05 (0.83 to 1.32)	–1.13 (–0.28 to 0.27)	**1.57 (1.23 to 1.99)**
Era 4	1.00 (0.89 to 1.12)	0.88 (0.68 to 1.12)	–0.22 (–0.37 to 0.06)	**1.61 (1.26 to 2.03)**

Bold indicates statistical significance in adjusted model. Multiple regression includes all variables and covariates of simple regression.
IMD categories 4 and 5 (most deprived) versus IMD categories 1, 2 and 3 (least deprived).
Era 1: 2003–2005, Era 2: 2006–2008, Era 3: 2009–2011, Era 4: 2012–2016.
First CS use: time to first CS prescription following diagnosis.
CS dependency: corticosteroid dependency defined as a repeat steroid prescription within 3 months of the end of a previous steroid prescription or patients with steroid prescriptions for greater than 3 consecutive months.
Hospitalisation: first IBD-related hospital admission following diagnosis.
Time to diagnosis: time from first primary care consultation for gastrointestinal symptom(s).
Consultation intensity: consultation frequency per person in the year prior to IBD diagnosis.
*See online supplemental appendix 5 for unadjusted analyses.
CS, corticosteroid; GI, gastrointestinal; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; IMD, Index of Multiple Deprivation.

DISCUSSION

Main findings

In this large population-based study we found more frequent primary care consultation for gastrointestinal symptoms prior to IBD diagnosis was associated with worse clinical IBD outcomes, notably an increased risk of surgery, and, with respect to UC, an increased risk of steroid dependency. Primary care consultation intensity was highest in the 1 year prior to diagnosis and in this year was associated with worse clinical outcomes in both CD and UC. Likewise, hospitalisation for gastrointestinal symptoms before diagnosis was associated with an increased risk of subsequent IBD-related hospital admission and intestinal surgery following diagnosis. A longer time to diagnosis, from the point of first primary care consult with gastrointestinal symptoms, was associated with increased disease-related hospitalisation in CD, but not surgery, and a milder disease course in UC.

Findings in relation to previous studies

To the best of our knowledge, this is the first nationally representative study to demonstrate an association between consultation frequency and intensity for gastrointestinal symptoms prior to diagnosis with subsequent adverse clinical outcomes following the diagnosis of IBD. Previous studies report a relationship between delayed diagnosis and adverse IBD-related clinical outcomes such as surgery.[2 29] However, the majority of these studies used retrospective questionnaires conducted in secondary healthcare settings, thus likely subject to both recall and referral centre bias.[6]

In our study, a longer time from first primary care consultation to diagnosis was associated with a subsequent increased hospitalisation for CD, but not surgery; in contrast, for UC, it was associated with a milder disease course. Our findings are similar to a previous study that also used UK primary care records, which reported no

associated risk between time to diagnosis and worse clinical outcomes.[30]

We also considered the impact of primary care consultation intensity for gastrointestinal symptoms prior to diagnosis, which was highest in the 1-year period immediately before diagnosis, and a greater consultation intensity in this year was associated with worse IBD outcomes. This reflects our previous observation that individuals with CD and UC were four times more likely to visit their primary care physician for gastrointestinal symptoms when compared with age-sex matched control groups without IBD between 18 and 6 months before diagnosis.[1] Repeat consultations may either be clinician or patient initiated, likely driven by both symptom frequency and severity. Our findings suggest that higher primary care consultation frequency and intensity before diagnosis are linked to a more aggressive/severe disease behaviour with worse outcomes, although the observed effects are relatively modest. This is in keeping with paediatric studies that show a short fulminant onset of symptoms is associated with worse clinical outcomes following UC diagnosis, including risk of colectomy.[31 32]

Hospitalisation for gastrointestinal symptoms prior to IBD diagnosis was more common in those from deprived postcodes and had an associated higher risk of adverse clinical outcomes following diagnosis. This is consistent with other findings that report emergency hospital presentation prior to diagnosis is associated with worse IBD-related clinical outcomes.[30]

Previous literature reporting the relationship between diagnostic delay and IBD outcomes is inconsistent, with several studies suggesting diagnostic delay based on self-reported symptom onset is associated with worse clinical outcomes following diagnosis,[2 33] while others have not.[30 34] The differences observed between this study and others may relate to how 'diagnostic delay' is defined. Most previous studies have measured total time to diagnosis, including both patient-related and healthcare-related delay, whereas our study measured the interval from first related primary care consult for gastrointestinal symptoms prior to IBD diagnosis. We found that a longer time to UC diagnosis was associated with a lower risk of subsequent hospitalisation and colectomy, suggesting this group may have a milder, more indolent disease course. Our findings are supported by the observation that asymptomatic or mildly symptomatic individuals, who are diagnosed with IBD at colonoscopy as part of bowel cancer screening initiatives, have a milder pattern of disease behaviour.[35] In contrast, a longer time to CD diagnosis was associated with a small increased risk of hospitalisation but not surgery which contrasts with most reports evaluating delay from the point of symptom onset.

The concept of the 'waiting time paradox', the effect that patients with severe symptoms indicative of a more aggressive and fulminant disease phenotype present rapidly over a short period of time, are diagnosed, and treated early, thereby leading to an apparent association between longer waits and better outcomes, has been reported for cancer diagnoses. It is considered an important source of bias in studies investigating the impact of diagnostic and treatment delays on cancer survival, where the biology of the disease may outweigh the impact of diagnostic delay when determining clinical outcomes.[36 37] Such a phenomenon may also be at play with regard to IBD whereby a fulminant disease course prior to diagnosis, rather than a long symptomatic period prior to diagnosis, may predict a more aggressive/severe disease course. This may be reflected in our findings, particularly regarding UC.

Guidelines recommend that clinicians investigate persistent non-specific gastrointestinal symptoms, which are also prevalent in other common gut disorders such as IBS.[38] Our study found that individuals with a prior diagnosis of IBS were more likely to have experienced a longer time to diagnosis and higher consultation frequency for gastrointestinal symptoms in the period before IBD diagnosis. It is possible individuals with undiagnosed IBD who receive a clinical diagnosis of IBS are less likely to be investigated, resulting in a longer time to diagnosis.[7] Similarly, we found that a prior diagnosis or symptoms of depression-anxiety were associated with both a longer time to diagnosis and increased consultation frequency for gastrointestinal symptoms in the period prior to IBD diagnosis. Gastrointestinal symptoms may be considered more likely to be of functional origin in these patients. In this respect, we have previously reported increased rates of depression following the onset of undiagnosed gastrointestinal symptoms in the lead up to a diagnosis of IBD.[15]

Strengths and limitations

We used data drawn from a large, validated, nationally representative, linked primary care and hospital database. CPRD data are collected at the time of consultation and therefore, unlike most previous studies that have relied on retrospective self-reported data from specialist centres, are free from recall and selection bias. There are limitations to the study design. We estimated time to diagnosis using captured data from primary care consultations and therefore cannot account for the duration of unreported symptoms prior to consultation. When interpreting the findings of our study, it is worth reflecting that they relate to patients with gastrointestinal symptoms presenting to primary care but other extraintestinal symptoms may also herald the onset of IBD.

We were unable to capture data on medications prescribed in the hospital setting, meaning rates of corticosteroid and immunomodulator use reported in this study are likely to be underestimated. However, in the UK, hospital outpatient prescribing is highly regulated, and primary care practices using shared care protocols enable general practitioners to accept the responsibility for the safe prescribing and monitoring of specialist medicines for patients with chronic conditions in the community. Therefore, it is likely that we would have

captured the large proportion of prescriptions, some of which may be only initiated in secondary care.

We were unable to identify episodes where individuals presented to the emergency department alone without requiring hospital admission, and thus the association between emergency hospital presentation and clinical outcomes may have been underestimated. Data defining endoscopic and radiological disease extent, or biochemical markers, such as C reactive protein and faecal calprotectin that are associated with disease severity, were not available for our analysis.

By choosing a methodology that included symptomatic individuals attending primary care in the 3 years before diagnosis, with no symptom in the preceding year, a small number of individuals may have been omitted but we chose this study design to minimise inclusion of consults for non-IBD-related gastrointestinal symptoms. This time interval was chosen since our previous findings revealed an excess of gastrointestinal symptoms in patients who later develop IBD compared with the background population emerged in this time frame.[1] We found no secular relationship by era of diagnosis regarding IBD outcomes (although hospitalisation prior to diagnosis was more common in the most recent era studied). This suggests diagnostic approaches seemingly have not altered time to diagnosis in the study period. More recently, the wider adoption of faecal calprotectin testing in primary care may allow more timely diagnosis. While the association of deprivation was evaluated, ethnicity was not reliably coded in the dataset and warrants evaluation in future work. Further work is also needed to determine if our observed findings are replicated in other healthcare systems.

Implications

Our findings highlight the need for expedited diagnostic approaches for patients who consult more frequently or intensely in primary care or require hospital admission for gastrointestinal symptoms. We speculate that some individuals with IBD who have a more aggressive disease behaviour do not necessarily present with a long duration of symptoms but instead with a rapidly progressive fulminant disease course, leading to a higher frequency and intensity of consultation and urgent hospital attendance in the period prior to IBD diagnosis. Clinicians need to be alert to the possibility of IBD when patients return repeatedly with unresolved symptoms. Prior healthcare use can alert clinicians to those at risk of a more aggressive IBD course, prompting targeted timely assessment. Further, prospective studies using newly described diagnostic and prognostic biomarker may shed further light on the relationship between symptom onset and healthcare use in the years before diagnosis and subsequent disease prognosis. Our findings, and those of others, indicate a significant burden of disease and healthcare use in the years before IBD diagnosis.[11 35 39] Diagnostic pathways that take account of patterns of healthcare consultation, alongside appropriate use of surrogate markers of inflammation such as faecal calprotectin, may enable expedited specialist referral and timely treatment.[38 39]

CONCLUSION

Consultation frequency, intensity and hospitalisation prior to diagnosis are associated with a subsequent risk of adverse IBD outcomes. Electronic healthcare records contain valuable information regarding patterns of consultation and may be used to expedite timely assessment and identify those at risk of aggressive forms of IBD.

Author affiliations
[1]Institute for Infection and Immunity, St George's University of London, London, UK
[2]Division of Epidemiology, Public Health and Primary Care, Imperial College London, London, UK
[3]Edinburgh Inflammatory Bowel Disease, Western General Hospital, Edinburgh, UK
[4]Research Department of Primary Care and Population Health, University College London, London, UK
[5]Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, London, UK

X Nishani Jayasooriya @jaya_nish

Collaborators Professor Richard C G Pollok, Professor Sonia Saxena, Professor Alex Bottle, Professor Irene Petersen, Dr Jonathan Blackwell, Dr Hanna Creese and Dr Nishani Jayasooriya

Contributors The POP-IBD study group is a collaboration between St George's University of London, Imperial College London, and University College London conducting population-based studies in the field of inflammatory bowel disease. NJ and JB prepared the data and carried out statistical analysis overseen by IP and AB. NJ and RCGP drafted the paper. All authors contributed to the concept, design, and interpretation of results, and commented on drafts of the manuscript. RCGP is the guarantor of this article.

Funding JB was funded by Crohn's and Colitis UK Grant [grant number: SP2018/3] SS is supported by an NIHR Senior investigator award (205021) and NIHR Applied Research Collaboration for Northwest London. SS and HC are supported by National Institute for Health and Care Research (NIHR) School for Public Health Research (SPHR), [Grant Reference Number NIHR 204000] The NIHR School for Public Health Research is a partnership between the Universities of Sheffield; Bristol; Cambridge; Imperial; and University College London; The London School for Hygiene and Tropical Medicine (LSHTM); LiLaC – a collaboration between the Universities of Liverpool and Lancaster; and Fuse - The Centre for Translational Research in Public Health a collaboration between Newcastle, Durham, Northumbria, Sunderland, and Teesside Universities. Professor Bottle's Unit at Imperial College London is affiliated with the NIHR Imperial Patient Safety Translational Research Centre. The NIHR Imperial Patient Safety Translational Centre is a partnership between the Imperial College Healthcare NHS Trust and Imperial College London. The School for Public Health Imperial College London is also grateful for support from the Imperial NIHR Biomedical Research Centre. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health Department of Health and Social Care.

Disclaimer The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Competing interests RCGP—advisory board for Galapagos; Celltrion educational sponsorship.

Patient consent for publication Not applicable.

Ethics approval CPRD and HES ethical and scientific approval for the study was granted by the Independent Scientific Advisory Committee (ISAC) on 8 January 2021 (Protocol approval number: 20_000248,website URL: https://cprd.com/protocol/impact-timely-diagnosis-and-recurrent-health-seeking-behaviour-subsequent-clinical-course-health-seeking-behaviour-subsequent-clinical-course).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available.

ORCID iDs
Nishani Jayasooriya http://orcid.org/0000-0003-1343-2446
Alex Bottle http://orcid.org/0000-0001-9978-2011
Richard C G Pollok http://orcid.org/0000-0001-6452-6763

REFERENCES

1 Blackwell J, Saxena S, Jayasooriya N, *et al*. Prevalence and duration of gastrointestinal symptoms before diagnosis of inflammatory bowel disease and predictors of timely specialist review: a population-based study. J Crohns Colitis2021;15:203–11.
2 Schoepfer A, Santos J, Fournier N, *et al*. Systematic analysis of the impact of diagnostic delay on bowel damage in paediatric versus adult onset crohn's disease. *J Crohns Colitis* 2019;13:1334–42.
3 Berg DR, Colombel JF, Ungaro R. The role of early biologic therapy in inflammatory bowel disease. *Inflamm Bowel Dis* 2019;25:1896–905.
4 Magro F, Rodrigues-Pinto E, Coelho R, *et al*. Is it possible to change phenotype progression in crohn's disease in the era of immunomodulators? Predictive factors of phenotype progression. *Am J Gastroenterol* 2014;109:1026–36.
5 Ramadas AV, Gunesh S, Thomas GAO, *et al*. Natural history of crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. *Gut* 2010;59:1200–6.
6 Jayasooriya N, Baillie S, Blackwell J, *et al*. POP-IBD study group. systematic review with meta-analysis: time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease. *Aliment Pharmacol Ther* 2023;57:635–52.
7 Card TR, Siffledeen J, Fleming KM. Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case-control study in the general practice research database. *UEG Journal* 2014;2:505–12.
8 Stapley SA, Rubin GP, Alsina D, *et al*. Clinical features of bowel disease in patients aged &50 years in primary care: a large case-control study. *Br J Gen Pract* 2017;67:e336–44.
9 Walker GJ, Moore L, Heerasing N, *et al*. Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. *Aliment Pharmacol Ther* 2018;47:1103–16.
10 Hawthorne AB, Glatter J, Blackwell J, *et al*. Inflammatory bowel disease patient-reported quality assessment should drive service improvement: a national survey of UK IBD units and patients. *Aliment Pharmacol Ther* 2022;56:625–45.
11 Vadstrup K, Alulis S, Borsi A, *et al*. Cost burden of crohn's disease and ulcerative colitis in the 10-year period before diagnosis-a Danish register-based study from 2003-2015. *Inflamm Bowel Dis* 2020;26:1377–82.
12 Bottle A, Kim D, Aylin P, *et al*. Routes to diagnosis of heart failure: observational study using linked data in England. *Heart* 2018;104:600–5.
13 Arhi CS, Markar S, Burns EM, *et al*. Delays in referral from primary care are associated with a worse survival in patients with esophagogastric cancer. *Dis Esophagus* 2019;32:1–11.
14 Herrett E, Gallagher AM, Bhaskaran K, *et al*. Data resource profile: clinical practice research datalink (CPRD). *Int J Epidemiol* 2015;44:827–36.
15 Blackwell J, Saxena S, Petersen I, *et al*. Depression in individuals who subsequently develop inflammatory bowel disease: a population-based nested case–control study. *Gut* 2021;70:1642–8.
16 Lewis JD, Brensinger C, Bilker WB, *et al*. Validity and completeness of the general practice research database for studies of inflammatory bowel disease. *Pharmacoepidemiol Drug Saf* 2002;11:211–8.
17 Chhaya V, Saxena S, Cecil E, *et al*. The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989–2009. *Aliment Pharmacol Ther* 2015;41:87–98.
18 Alexakis C, Saxena S, Chhaya V, *et al*. Smoking status at diagnosis and subsequent smoking cessation: associations with corticosteroid use and intestinal resection in crohn's disease. *Am J Gastroenterol* 2018;113:1689–700.
19 Van Assche G, Dignass A, Panes J, *et al*. The second European evidence-based consensus on the diagnosis and management of crohn's disease: definitions and diagnosis. *J Crohns Colitis* 2010;4:7–27.
20 Blackwell J, Saxena S, Alexakis C, *et al*. The impact of smoking and smoking cessation on disease outcomes in ulcerative colitis: a nationwide population-based study. *Aliment Pharmacol Ther* 2019;50:556–67.
21 Ahmad A, Laverty AA, Alexakis C, *et al*. Changing nationwide trends in endoscopic, medical and surgical admissions for inflammatory bowel disease: 2003–2013. *BMJ Open Gastroenterol* 2018;5:e000191.
22 Dai Z, Ma Y, Zhan Z, *et al*. Analysis of diagnostic delay and its influencing factors in patients with chronic obstructive pulmonary disease: a cross-sectional study. *Sci Rep* 2021;11:14213:14213:.
23 Duricova D, Burisch J, Jess T, *et al*. Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. J Crohns Colitis2014;8:1351–61.
24 Fairbrass KM, Lovatt J, Barberio B, *et al*. Bidirectional brain-gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis. *Gut* 2022;71:1773–80.
25 Umar N, King D, Chandan JS, *et al*. The association between inflammatory bowel disease and mental ill health: a retrospective cohort study using data from UK primary care. *Aliment Pharmacol Ther* 2022;56:814–22.
26 Blackwell J, Alexakis C, Saxena S, *et al*. Association between antidepressant medication use and steroid dependency in patients with ulcerative colitis: a population-based study. *BMJ Open Gastroenterol* 2021;8:e000588.
27 Yohannes AM, Willgoss TG, Baldwin RC, *et al*. Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles. *Int J Geriatr Psychiatry* 2010;25:1209–21.
28 Marston L, Carpenter JR, Walters KR, *et al*. Smoker, ex-smoker or non-smoker? The validity of routinely recorded smoking status in UK primary care: a cross-sectional study. *BMJ Open* 2014;4:e004958.
29 Hong Z, Ren J, Li Y, *et al*. Delayed diagnosis is associated with early and emergency need for first Crohn's disease-related intestinal surgery. *Med Sci Monit* 2017;23:4841–6.
30 Walker GJ, Lin S, Chanchlani N, *et al*. Quality improvement project identifies factors associated with delay in IBD diagnosis. *Aliment Pharmacol Ther* 2020;52:471–80.
31 Krishna M, Britto S, Qian J, *et al*. Diagnostic delay and colectomy risk in pediatric ulcerative colitis. *J Pediatr Surg* 2020;55:403–5.
32 Rinawi F, Assa A, Eliakim R, *et al*. Risk of colectomy in patients with pediatric-onset ulcerative colitis. *J Pediatr Gastroenterol Nutr* 2017;65:410–5.
33 Kang HS, Koo JS, Lee KM, *et al*. Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use. *World J Gastroenterol* 2019;25:989–1001.
34 Zaharie R, Tantau A, Zaharie F, *et al*. Diagnostic delay in Romanian patients with inflammatory bowel disease: risk factors and impact on the disease course and need for surgery. *J Crohns Colitis* 2016;10:306–14.
35 Rodríguez-Lago I, Merino O, Azagra I, *et al*. Characteristics and progression of preclinical inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2018;16:1459–66.
36 Hanna TP, King WD, Thibodeau S, *et al*. Mortality due to cancer treatment delay: systematic review and meta-analysis. *BMJ* 2020;371:m4087.
37 Neal RD, Tharmanathan P, France B, *et al*. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. *Br J Cancer* 2015;112 Suppl 1:S92–107.
38 Lamb CA, Kennedy NA, Raine T, *et al*. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut* 2019;68:s1–106.
39 Rodríguez-Lago I, Agirre U, Intxaurza N, *et al*. Increased use of healthcare resources during the preclinical period of inflammatory bowel disease. *Dig Liver Dis* 2021;53:927–30.

SUPPLEMENTARY MATERIAL

Appendix 1 -Read codes

List of CPRD med-codes used in the definition of gastrointestinal symptoms

Diarrhoea

Description	Medcode
Diarrhoea symptoms	5134
Diarrhoea	192
Diarrhoea	4343
Loose stools	1695
Chronic diarrhoea	6685
Diarrhoea of presumed infectious origin	5090
Diarrhoea symptom NOS	14695
Noninfective diarrhoea	6016
Functional diarrhoea	5036
Increased frequency of defaecation	18682
[D] Stools loose	14881
Irritable bowel syndrome with diarrhoea	29835
Infectious diarrhoea	4542
Gastroenteritis	139
Diarrhoea & vomiting, symptom	2182
Diarrhoea and vomiting	7644
Viral gastroenteritis	3107
Diarrhoea & vomiting -? Infect	14665
[D]Change in bowel habit	[16665
Travellers' diarrhoea	11155
Viral diarrhoea	15289
Infectious gastroenteritis	10294

Abdominal or perianal pain

Description	Medcode
Abdominal pain	177
[D]Abdominal pain	1763
Abdominal pain type	1976
Abdominal discomfort	2383
Anal pain	3049
Right iliac fossa pain	1181
[D]Abdominal colic 2056	2056

Left iliac fossa pain 2982	2982
Colicky abdominal pain	7812
Rectal pain	2767
[D]Abdominal cramps	716
O/E - abdomen tender	5782
[D]Abdominal pain NOS	3338
Site of abdominal pain	5960
Lower abdominal pain	22608
Central abdominal pain	4617
Flank pain	7490
[D]Nonspecific abdominal pain	19283
[D]Functional abdominal pain syndrome	103540
Iliac fossa pain	421
[D]Acute abdomen	948
O/E - abdo. pain on palpation	15180
Anorectal pain	2866
Generalised abdominal pain	24661
O/E -abd.pain on palpation NOS	14916
O/E - abd. pain - L.iliac	21583
Non-colicky abdominal pain	5691
Abdominal pain in pregnancy	3191
[D]Pain in left iliac fossa	16868
[D]Pain in right iliac fossa	16806
O/E - abd. pain - R.iliac	11647
C/O pelvic pain	2781
Suprapubic pain	7300
Perianal irritation	9837
[D]Colic NOS	1239
Perianal itch	5830
[D]Epigastric pain	542
Perineal irritation	7090
[D] Perineal pain	7248
[D]Pelvic and perineal pain	9920
[D]Recurrent acute abdominal pain	2234
Upper abdominal pain	3978
Right upper quadrant pain	9695
[D]Right upper quadrant pain	7726
O/E - abd. pain – epigastrium	19223
[D]Upper abdominal pain	8436
Left flank pain	701
Epigastric pain	290
[D]Flatulence, eructation and gas pain	14807
Type of GIT pain	14989
Type of GIT pain – symptom	6395
[D]Umbilical pain	4771

Rectal Bleeding

Description	**Medcode**

Rectal bleeding	621
Bleeding PR	3872
Painless rectal bleeding	11698
Painful rectal bleeding	11718
Blood in stool	2873
Blood in faeces	5462
Blood in faeces symptom	6151
Gastrointestinal haemorrhage	3097
GIB – Gastrointestinal bleeding	1642
Haemorrhoids	195
Piles - haemorrhoids	3833
Haemorrhoids NOS	2096
Bleeding haemorrhoids NOS	2832
PRB – Rectal bleeding	6554

Diarrhoea

Description	**ICD-10 Code**
Functional diarrhoea	K59.1
Protozoal intestinal disease, unspecified	A07.9
Flagellate diarrhoea	
Protozoal:	
colitis	
diarrhoea	
dysentery	
Viral and other specified intestinal infections	A08
Excl.:	
influenza with involvement of gastrointestinal tract (J09, J10.8, J11.8)	
Rotaviral enteritis	A08.0
Acute gastroenteropathy due to Norwalk agent	A08.1
Small round structured virus enteritis	
Adenoviral enteritis	A08.2
Other viral enteritis	A08.3
Viral intestinal infection, unspecified	A08.4
Viral:	
enteritis NOS	
gastroenteritis NOS	
gastroenteropathy NOS	
Other specified intestinal infections	A08.5
Other gastroenteritis and colitis of infectious and unspecified origin	A09
Excl.:	
due to bacterial, protozoal, viral and other specified infectious agents (A00-A08)	
noninfective (see noninfectious) diarrhoea (K52.9)	
noninfective (see noninfectious) diarrhoea	
neonatal (P78.3)	

Other and unspecified gastroenteritis and colitis of infectious origin	A09.0
Catarrh, enteric or intestinal	
Diarrhoea:	
acute bloody	
acute haemorrhagic	
acute watery	
dysenteric	
epidemic	
Infectious or septic	
colitis	
enteritis	
gastroenteritis	
NOS	
haemorrhagic	
Infectious diarrhoea NOS	
Gastroenteritis and colitis of unspecified origin	A09.9
Chronic intestinal amoebiasis	A06.1
Amoebic nondysenteric colitis	A06.2
Amoeboma of intestine	A06.3
Amoeboma NOS	
Noninfective gastroenteritis and colitis, unspecified	K52.9
Diarrhoea	
Enteritis	
Ileitis	
Jejunitis	
Sigmoiditis	
specified as noninfectious	
Excl.:	
colitis, diarrhoea, enteritis, gastroenteritis:	
infectious (A09.0)	
unspecified origin (A09.9)	
functional diarrhoea (K59.1)	
neonatal diarrhoea (noninfective) (P78.3)	
psychogenic diarrhoea (F45.3)	
Vascular disorder of intestine, unspecified	K55.9
Ischaemic:	
colitis	
enteritis	
enterocolitis	
NOS	
Gastroenteritis and colitis due to radiation	K52.0
Toxic gastroenteritis and colitis	K52.1
Use additional external cause code (Chapter XX), if desired, to identify toxic agent.	
Allergic and dietetic gastroenteritis and colitis	K52.2
Food hypersensitivity gastroenteritis or colitis	
Noninfective gastroenteritis and colitis, unspecified	K52.9
Diarrhoea	
Enteritis	

Ileitis	
Jejunitis	
Sigmoiditis	
specified as noninfectious	
Excl.:	
colitis, diarrhoea, enteritis, gastroenteritis:	
infectious (A09.0)	
unspecified origin (A09.9)	
functional diarrhoea (K59.1)	
neonatal diarrhoea (noninfective) (P78.3)	
psychogenic diarrhoea (F45.3)	
psychogenic diarrhoea	F45.3
Irritable bowel syndrome with diarrhoea	K58.0

Abdominal or perianal pain

Description	**ICD-10 Code**
Acute abdomen	R10.0
Severe abdominal pain (generalized)(localized)(with abdominal rigidity)	
Pain localized to upper abdomen	R10.1
Epigastric pain	
Pelvic and perineal pain	R10.2
Pain localized to other parts of lower abdomen	R10.3
Other and unspecified abdominal pain	R10.4
Abdominal tenderness NOS	
Colic:	
NOS	
Infantile	
Other specified disease of anus and rectum	K62.8
Pain | rectum	

Rectal bleeding

Description	**ICD-10 Code**
Internal haemorrhoids with other complications	I84.1
Internal haemorrhoids:	
bleeding	
prolapsed	
strangulated	
ulcerated	
Internal haemorrhoids without complication	I84.2
Internal haemorrhoids NOS	

External thrombosed haemorrhoids	I84.3
Perianal haematoma (nontraumatic)	
Perianal thrombosis	
External haemorrhoids with other complications	I84.4
External haemorrhoids:	
bleeding	
prolapsed	
strangulated	
ulcerated	
External haemorrhoids without complication	I84.5
External haemorrhoids NOS	
I84.6	
Residual haemorrhoidal skin tags	
Skin tags of anus or rectum	
Unspecified thrombosed haemorrhoids	I84.7
Thrombosed haemorrhoids, unspecified whether internal or external	
Unspecified haemorrhoids with other complications	I84.8
Haemorrhoids, unspecified whether internal or external:	
bleeding	
prolapsed	
strangulated	
ulcerated	
Unspecified haemorrhoids without complication	I84.9
Haemorrhoids NOS	
Other faecal abnormalities	R19.5
Abnormal stool colour	
Bulky stools	
Mucus in stools	
Occult blood in stools	
Excl.:	
melaena (K92.1)	
melaena	
Haemorrhage of anus and rectum	K62.5
Gastrointestinal haemorrhage, unspecified	K92.2
Haemorrhage:	
gastric NOS	
intestinal NOS	
Excl.:	
acute haemorrhagic gastritis (K29.0)	
haemorrhage of anus and rectum (K62.5)	
with peptic ulcer (K25-K28)	

List of CPRD prod-codes for corticosteroid prescriptions

Prodcode	Product Name
5913	Deltacortril 2.5mg gastro-resistant tablets (Alliance Pharmaceuticals Ltd)
5490	Deltacortril 5mg gastro-resistant tablets (Alliance Pharmaceuticals Ltd)
27962	Deltastab 1mg Tablet (Waymade Healthcare Plc)
28859	Deltastab 5mg Tablet (Waymade Healthcare Plc)
59283	Dilacort 2.5mg gastro-resistant tablets (Auden McKenzie (Pharma Division) Ltd)
59229	Dilacort 5mg gastro-resistant tablets (Auden McKenzie (Pharma Division) Ltd)
25272	Precortisyl 1mg Tablet (Hoechst Marion Roussel)
23512	Precortisyl 5mg Tablet (Hoechst Marion Roussel)
20095	Precortisyl forte 25mg Tablet (Aventis Pharma)
10934	Predenema 20mg/100ml long tube (Forest Laboratories UK Ltd)
58234	Prednisolone 10mg/5ml oral solution
34914	Prednisolone 1mg Tablet (Celltech Pharma Europe Ltd)
34631	Prednisolone 1mg Tablet (Co-Pharma Ltd)
578	Prednisolone 1mg tablets
34452	Prednisolone 1mg tablets (A A H Pharmaceuticals Ltd)
34404	Prednisolone 1mg tablets (Actavis UK Ltd)
58384	Prednisolone 1mg tablets (Almus Pharmaceuticals Ltd)
34660	Prednisolone 1mg tablets (Kent Pharmaceuticals Ltd)
34748	Prednisolone 1mg tablets (Teva UK Ltd)
56891	Prednisolone 1mg tablets (Waymade Healthcare Plc)
34978	Prednisolone 1mg tablets (Wockhardt UK Ltd)
59338	Prednisolone 1mg/5ml oral solution
28376	Prednisolone 2.5mg Gastro-resistant tablet (Biorex Laboratories Ltd)
557	Prednisolone 2.5mg gastro-resistant tablets
28375	Prednisolone 2.5mg gastro-resistant tablets (A A H Pharmaceuticals Ltd)
34461	Prednisolone 2.5mg gastro-resistant tablets (Actavis UK Ltd)
2368	Prednisolone 2.5mg tablet
54434	Prednisolone 2.5mg/5ml oral suspension
38407	Prednisolone 20mg tablet
820	Prednisolone 20mg/100ml retention enema
53313	Prednisolone 20mg/5ml oral suspension
2704	Prednisolone 25mg tablets
41745	Prednisolone 25mg tablets (Zentiva)
54118	Prednisolone 25mg/5ml oral suspension
42408	Prednisolone 40mg/100ml enema
34109	Prednisolone 5 mg gastro-resistant tablet
9727	Prednisolone 50mg tablets
33691	Prednisolone 5mg Gastro-resistant tablet (Biorex Laboratories Ltd)
45302	Prednisolone 5mg Tablet (Biorex Laboratories Ltd)
33988	Prednisolone 5mg Tablet (Co-Pharma Ltd)
33990	Prednisolone 5mg Tablet (IVAX Pharmaceuticals UK Ltd)
44	Prednisolone 5mg gastro-resistant tablets
31532	Prednisolone 5mg gastro-resistant tablets (A A H Pharmaceuticals Ltd)
32803	Prednisolone 5mg gastro-resistant tablets (Actavis UK Ltd)
34393	Prednisolone 5mg gastro-resistant tablets (Teva UK Ltd)
59912	Prednisolone 5mg gastro-resistant tablets (Waymade Healthcare Plc)
95	Prednisolone 5mg tablets

21417	Prednisolone 5mg tablets (A A H Pharmaceuticals Ltd)
29333	Prednisolone 5mg tablets (Actavis UK Ltd)
58000	Prednisolone 5mg tablets (Almus Pharmaceuticals Ltd)
34781	Prednisolone 5mg tablets (Kent Pharmaceuticals Ltd)
41515	Prednisolone 5mg tablets (Teva UK Ltd)
61162	Prednisolone 5mg tablets (Waymade Healthcare Plc)
32835	Prednisolone 5mg tablets (Wockhardt UK Ltd)
55024	Prednisolone 5mg/5ml oral solution
34221	Prednisolone suppositories
16525	Budenofalk 3mg gastro-resistant capsules (Dr. Falk Pharma UK Ltd)
56144	Budenofalk 9mg gastro-resistant granules sachets (Dr. Falk Pharma UK Ltd)
6095	Budesonide 3mg gastro-resistant capsules
51997	Budesonide 9mg gastro-resistant granules sachets
1380	Entocort CR 3mg capsules (AstraZeneca UK Ltd

List of CPRD Read Codes for IBS diagnosis

Read Code	Read Term
Eu453	[X]Psychogenic IBS
J521.	Irritable bowel syndrome
J5210	Irritable bowel syndrome with diarrhoea
J5211	Irritable bowel syndrome characterised by constipation
J5212	Irritable bowel syndrome characterised by alternating bowel habit

Appendix 2-Flow diagram of patients stratified by primary care consultation frequency and hospitalisation prior to IBD diagnosis



*** All individuals had at least four years of follow-up from registering with their general practice before IBD diagnosis, and the first of these years free of any record of gastrointestinal symptoms. Abbreviations CD: Crohn's Disease; UC: Ulcerative colitis**

Appendix 3: Association of time to diagnosis, consultation frequency and hospitalisation for gastrointestinal symptoms before diagnosis with clinical outcomes following diagnosis of (a) Crohn's disease (b) Ulcerative colitis

(a) Crohn's disease

	CS use		CS dependency		IM use		IBD Hospitalisation		Intestinal surgery		Perianal surgery	
	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)
Consultation frequency												
1	-	-	-	-	-	-	-	-	-	-	-	-
2	0.90 (0.70-1.18)	0.90 (0.68-1.18)	1.11 (0.75-1.64)	1.11 (0.74-1.65)	1.09 (0.81-1.47)	1.05 (0.78-1.43)	1.78 (1.24-2.54)	1.35 (0.94-1.93)	1.49 (0.94-2.36)	1.58 (0.99-2.51)	1.13 (0.86-1.48)	1.08 (0.81-1.44)
≥ 3	1.18 (0.94-1.49)	1.21 (0.94-1.56)	1.23 (0.87-1.75)	1.23 (0.84-1.80)	1.14 (0.88-1.48)	1.11 (0.84-1.52)	1.76 (1.27-2.44)	**1.80 (1.29-2.50)**	2.13 (1.44-3.16)	**2.22 (1.45-3.39)**	1.12 (0.88-1.43)	1.00 (0.79-1.36)
Time to diagnosis	0.92 (0.81-1.03)	0.89 (0.78-1.01)	0.68 (0.79-1.12)	0.89 (0.73-1.07)	0.94 (0.74-1.22)	0.92 (0.80-1.06)	0.98 (0.84-1.15)	**1.03 (1.01-1.68)**	0.99 (0.82-1.19)	0.87 (0.71-1.06)	1.01 (0.87-1.14)	1.00 (0.88-1.15)
Pre-diagnosis hospital admission	1.03 (0.82-1.30)	0.96 (0.76-1.21)	0.94 (0.50-0.93)	1.05 (0.78-1.42)	0.95 (0.82-1.07)	0.78 (0.60-1.01)	1.42 (1.09-1.84)	**1.30 (1.01-1.68)**	1.77 (1.18-2.68)	**1.71 (1.13-2.58)**	1.37 (1.11-1.69)	1.19 (0.96-1.48)
Sex												
Female	-	-	-	-	-	-	-	-	-	-	-	-
Male	1.11 (0.91-1.35)	1.13 (0.55-0.86)	0.76 (0.58-1.04)	0.85 (0.62-1.15)	1.16 (0.93-1.45)	1.04 (0.83-1.32)	1.14 (0.87-1.48)	1.12 (0.87-1.44)	1.11 (0.82-1.53)	1.20 (0.86-1.66)	1.16 (0.94-1.43)	1.05 (0.84-1.30)
Age at IBD diagnosis												
> 40 years	-	-	-	-	-	-	-	-	-	-	-	-
< 17 years	1.50 (1.21-1.86)	**1.45** (1.00-2.09)	1.06 (0.63-1.79)	1.20 (0.68-2.12)	3.67 (2.63-5.10)	**3.60 (2.47-5.24)**	2.78 (1.86-4.15)	**2.31 (1.51-3.56)**	0.86 (0.47-1.58)	0.71 (0.37-1.36)	1.55 (1.11-1.46)	**1.72 (1.18-2.51)**
17 - 40 years	**1.50 (1.21- 1.87)**	**1.46 (1.16-1.83)**	1.36 (0.98-1.86)	1.26 (0.90-1.76)	1.79 (1.37- 2.33)	**1.89 (1.43-2.49)**	1.77 (1.34-2.33)	**1.52 (1.14- 2.03)**	1.41 (1.00-1.98)	1.18 (0.83-1.68)	1.17 (0.93-1.46)	1.27 (0.99-1.62)
Era of IBD diagnosis												
Era 1	-	-	-	-	-	-	-	-	-	-	-	-
Era 2	1.06 (0.81-1.39)	1.07 (0.82-1.42)	0.89 (0.60-1.31)	0.88 (0.59-1.29)	1.47 (1.03-2.07)	1.50 (0.66-1.41)	1.28 (0.88-1.85)	1.18 (0.83-1.69)	1.25 (0.81-1.94)	1.34 (0.86-2.08)	1.35 (0.96-1.88)	1.37 (0.98-1.92)
Era 3	0.94 (0.71-1.26)	0.90 (0.91-0.68)	0.73 (0.48-1.11)	0.72 (0.47-1.11)	1.97 (1.40-2.79)	**2.02 (1.41-1.26)**	1.19 (0.80-1.75)	1.15 (0.80-1.65)	1.33 (0.84-2.08)	1.29 (0.81-2.06)	**2.25 (1.62-3.11)**	**2.21 (1.58-3.09)**
Era 4	1.34 (1.01-1.77)	1.32 (0.99-1.77)	0.77 (0.50-1.17)	0.76 (0.49-1.18)	3.31 (2.34-4.65)	**3.32 (2.34-4.74)**	1.88 (1.28-2.76)	**2.00 (1.35-2.98)**	1.29 (0.80-2.07)	1.25 (0.76-2.04)	**4.78 (3.48-6.55)**	**4.54 (3.28-6.28)**
Smoking status*												

Never	-	-	-	-	-	-	-	-	-	-	-	-
Ex-smoker	0.95 (0.72-1.25)	0.85 (0.61-1.18)	1.22 (0.83-1.83)	0.90 (0.55-1.48)	0.83 (0.60-1.14)	0.91 (0.65-1.26)	0.90 (0.63-1.31)	0.60 (0.38-0.93)	0.97 (0.64-1.47)	0.96 (0.63-1.46)	0.82 (0.60-1.12)	0.94 (0.67-1.31)
Current	0.78 (0.61-1.01)	0.99 (0.75-1.31)	0.80 (0.50-1.31)	1.22 (0.82-1.83)	0.93 (0.70-1.23)	0.88 (0.65-1.19)	0.91 (0.66-1.24)	1.05 (0.75-1.48)	0.67 (0.45-0.99)	0.76 (0.50-1.16)	0.80 (0.60-1.06)	0.90 (0.67-1.20)
Social deprivation												
IMD 1-3	-	-	-	-	-	-	-	-	-	-	-	-
IMD 4-5	1.20 (0.99-1.48)	1.12 (0.91-1.39)	1.23 (0.91-1.66)	1.14 (0.83-1.56)	1.16 (0.92-1.47)	0.97 (0.76-1.24)	1.16 (0.88-1.52)	1.12 (0.86-1.46)	1.21 (0.87-1.67)	1.11 (0.80-1.55)	1.02 (0.82-1.27)	0.87 (0.69-1.08)

(b) Ulcerative Colitis

	CS use		**CS dependency**		**IM use**		**IBD-Hospitalisation**		**Colectomy**	
	Unadjusted HR (95% CI)	**Adjusted HR (95% CI)**	**Unadjusted HR (95% CI)**	**Adjusted HR (95% CI)**	**Unadjusted HR (95% CI)**	**Adjusted HR (95% CI)**	**Unadjusted HR (95% CI)**	**Adjusted HR (95% CI)**	**Unadjusted HR (95% CI)**	**Adjusted HR (95% CI)**
Consultation frequency										
1	-	-	-	-	-	-	-	-	-	-
2	1.22 (1.01-1.48)	**1.26 (1.04-1.60)**	1.27 (0.94-1.73)	1.28 (0.94-1.75)	1.15 (0.86-1.54)	1.12 (0.83-1.51)	1.33 (0.97-1.81)	1.24 (0.93-1.66)	0.86 (0.51-1.44)	0.93 (0.55-1.57)
≥ 3	1.53 (1.27-1.84)	**1.60 (1.31-1.96)**	1.72 (1.29-2.31)	**1.76 (1.28-2.41)**	1.71 (1.30-2.24)	**1.68 (1.24-2.26)**	1.66 (1.23-2.44)	**1.43 (1.05-1.95)**	1.57 (0.99-2.46)	**2.01 (1.22-3.27)**
Time to diagnosis	0.96 (0.87-1.05)	**0.87 (0.79-0.97)**	1.04 (0.90-1.20)	0.95 (0.81-1.11)	0.98 (0.86-1.13)	0.88 (0.76-1.03)	0.91 (0.78-1.06)	**0.83 (0.70-0.98)**	0.71 (0.54- 0.95)	**0.59 (0.43- 0.80)**
Pre-diagnosis hospital admission	1.25 (1.06-1.46)	1.18 (0.99-1.39)	1.10 (0.85-1.42)	1.04 (0.80-1.36)	1.51 (1.19-1.91)	**1.42 (1.11-1.81)**	1.58 (1.22-2.03)	**1.36 (1.06-1.95)**	1.41 (0.94-2.11)	**1.54 (1.01-2.34)**
Sex										
Female	-	-	-	-	-	-	-	-	-	-
Male	1.01 (0.86-1.18)	1.00 (0.85-1.17)	1.31 (1.02-1.69)	**1.37 (1.06-1.76)**	1.17 (0.92-1.47)	1.16 (0.92-1.48)	0.97 (0.75-1.25)	1.01 (0.79-1.29)	1.45 (0.96-2.19)	1.42 (0.93-2.16)
Age at IBD diagnosis										
>40	-	-	-	-	-	-	-	-	-	-
<17	1.88 (1.302.72)	**1.82 (1.24-2.69)**	2.41 (1.44-4.04)	**2.38 (1.37-4.12)**	3.40 (2.17-5.32)	**3.35 (2.07-5.43)**	3.54 (2.19-5.71	**3.40 (1.47-1.89)**	2.77 (1.25-6.11)	**2.54 (1.09-5.95)**
17 – 39	**1.39 (1.18- 1.63)**	**1.34 (1.14-1.60)**	1.55 (1.20-2.00)	**1.52 (1.17-1.98)**	1.87 (0.46- 2.38)	**1.83 (1.42-2.34)**	1.56 (1.22-2.00)	**1.47 (1.14- 1.89)**	1.68 (1.11- 2.55)	**1.81 (1.17-2.79)**
Era of IBD diagnosis										

Era 1	-	-	-	-	-	-	-	-	-	-
Era 2	1.16 (0.93-1.45)	1.14 (0.92-1.43)	1.04 (0.76-1.43)	1.05 (0.76-1.44)	1.15 (0.81-1.62)	1.11 (0.78-1.57)	0.91 (0.64-1.30)	0.82 (0.58-1.13)	0.73 (0.43-1.22)	0.65 (0.38-1.09)
Era 3	1.42 (1.14-1.78)	**1.35 (1.07-1.70)**	0.89 (0.63-1.26)	0.83 (0.58-1.20)	1.71 (1.23-2.39)	**1.53 (1.08-2.15)**	1.05 (0.73-1.50)	0.91 (0.66-1.29)	0.76 (0.43-1.31)	0.62 (0.35-1.11)
Era 4	1.49 (1.17-1.89)	**1.44 (1.14-1.83)**	0.80 (0.55-1.17)	0.76 (0.52-1.12)	2.06 (1.45-2.93)	**1.95 (1.36-2.80)**	1.56 (1.09-2.23)	1.15 (0.79-1.58)	0.93 (0.52-1.67)	0.85 (0.46-1.54)
Smoking status*										
Never	-	-	-	-	-	-	-	-	-	-
Ex-smoker	0.89 (0.73-1.10)	0.94 (0.99-1.54)	0.83 (0.60-1.15)	0.88 (0.63-1.23)	0.78 (0.57-1.05)	0.89 (0.64-1.22)	0.59 (0.42- 0.84)	0.79 (0.51-1.03)	1.15 (0.66-1.99)	1.33 (0.75-2.34)
Current	0.93 (0.68-1.29)	0.97 (1.13-1.79)	0.64 (0.37-1.15)	0.59 (0.32-1.05)	0.80 (0.49-1.30)	0.81 (0.49-1.32)	0.70 (0.40-1.22)	0.78 (0.48-1.30)	0.98 (0.39-2.43)	0.89 (0.36-2.20)
Social deprivation										
IMD 1-3	-	-	-	-	-	-	-	-	-	-
IMD 4-5	1.11 (0.94-1.31)	1.06 (0.89-1.26)	0.94 (0.72-1.24)	0.91 (0.69-1.1)	0.89 (0.69-1.16)	0.79 (0.61-1.02)	1.40 (1.08-1.82)	1.26 (0.98-1.62)	0.72 (0.44-1.16)	0.65 (0.40-1.05)

Bold indicates statistical significance in adjusted model. CS, Corticosteroids; IM, Immunomodulator; HR, Hazard Ratio; CI, confidence interval; IMD, index of multiple deprivations

IMD categories 4 and 5 [most deprived] vs IMD categories 1, 2 and 3 [least deprived]

Era 1: 2003 – 2005, Era 2 2006 – 2008, Era 3 2009 – 2011 and Era 4 2012 – 2016

First CS use: Time to first CS prescription following diagnosis

CS dependency: Corticosteroid dependency defined as a repeat steroid prescription within 3 months of the end of a previous steroid prescription or patients with steroid prescriptions for greater than 3 consecutive months

Hospitalisation: IBD-related hospital admission following diagnosis

Time to diagnosis: Time from first primary care consultation for gastrointestinal symptom(s)

Appendix 4: Association of consultation intensity with gastrointestinal symptoms before diagnosis with clinical outcomes following (a) Crohn's disease diagnosis (b) Ulcerative colitis

(a) Crohn's disease

Year before diagnosis	CS use		CS dependency		IM use		IBD Hospitalisation		Intestinal surgery		Perianal surgery	
	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)
Year 1	1.08 (1.02-1.14)	1.03 (0.98-1.08)	1.06 (0.98-1.15)	1.01 (0.96-1.07)	0.99 (0.94-1.04)	1.00 (0.95-1.06)	1.19 (1.12-1.26)	**1.19 (1.12-1.28)**	1.11 (1.03-1.20)	**1.13 (1.03-1.23)**	1.01 (0.95-1.07)	1.05 (0.98-1.13)
Year 2	0.99 (0.89-1.09)	1.00 (0.92-1.09)	1.00 (0.86-1.17)	0.99 (0.90-1.09)	1.02 (0.94-1.12)	1.03 (0.94-1.12)	1.12 (1.00 -1.24)	**1.13 (1.01-1.25)**	0.90 (0.74-1.08)	0.86 (0.71-1.03)	1.01 (0.92-1.12)	1.00 (0.90-1.12)
Year3	0.93 (0.81-1.07)	0.96 (0.95-1.08)	1.03 (0.87-1.23)	0.99 (0.88-1.11)	0.92 (0.82-1.04)	0.90 (0.80-1.02)	1.09 (0.90-1.31)	1.10 (0.91 -1.33)	1.18 (0.99-1.42)	1.25 (0.99-1.48)	1.02 (0.91-1.48)	0.98 (0.87-1.11)

(b) Ulcerative colitis

Year before diagnosis	CS use		CS dependency		IM use		IBD Hospitalisation		Colectomy	
	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)
Year 1	1.16 (1.10-1.21)	**1.08 (1.04-1.13)**	1.22 (1.13-1.31)	1.05 (1.00-1.11)	1.01 (0.97-1.06)	1.03 (0.98-1.08)	1.14 (1.05-1.24)	**1.12 (1.03-1.21)**	1.14 (1.00-1.28)	1.12 (0.99-1.26)
Year 2	1.09 (0.99-1.19)	1.03 (0.96-1.11)	1.23 (1.09-1.39)	1.07 (0.98-1.15)	1.03 (0.94-1.12)	1.03 (0.95-1.13)	1.08 (0.94-1.24)	1.05 (0.92-1.20)	0.92 (0.68-1.23)	0.91 (0.68-1.20)
Year 3	0.98 (0.87-1.12)	1.02 (0.93-1.12)	1.03 (0.85-1.24)	1.05 (0.96-1.16)	1.00 (0.91-1.11)	1.03 (0.93-1.13)	0.96 (0.78-1.18)	1.00 (0.81-1.23)	1.00 (0.73-1.37)	1.00 (0.73-1.28)

Bold indicates statistical significance in adjusted model. CS, Corticosteroids; IM, Immunomodulator; HR, Hazard Ratio; CI, confidence interval; IMD, index of multiple deprivations

IMD categories 4 and 5 [most deprived] vs IMD categories 1, 2 and 3 [least deprived]

Era 1: 2003 – 2005, Era 2 2006 – 2008, Era 3 2009 – 2011 and Era 4 2012 – 2016

First CS use: Time to first CS prescription following diagnosis

CS dependency: Corticosteroid dependency defined as a repeat steroid prescription within 3 months of the end of a previous steroid prescription or patients with steroid prescriptions for greater than 3 consecutive months

Hospitalisation: IBD-related hospital admission following diagnosis

Consultation intensity consultation frequency per person, as a continuous variable, in each individual year over the 3-year period before diagnosis

Appendix 5 Factors associated with time to diagnosis, consultation frequency, consultation intensity and hospitalisation before diagnosis of IBD

	Time to diagnosis		Consultation frequency		Consultation Intensity		Prior GI hospitalisation	
	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Unadjusted Coefficient (95% CI)	Adjusted Coefficient (95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Age								
> 40	-	-	-	-	-	-	-	-
< 17	1.05 (0.90 - 1.06)	0.99 (0.82 - 1.17)	1.71 (1.44 – 2.03)	**2.32 (1.40 - 2.01)**	0.01 (-0.14 - 0.14)	**0.44 (0.20 - 0.67)**	**1.62 (1.15 - 2.27)**	**1.74 (1.21 - 2.48)**
17-39	0.98 (0.89 - 1.25)	0.99 (0.91 - 1.07)	1.75 (1.23 – 2.47)	**1.68 (1.60 – 3.38)**	0.07 (0.01 - 0.14)	**0.37 (0.25 - 0.48)**	0.96 (0.81 - 1.13)	0.95 (0.80 - 1.14)
Sex								
Male	-	-	-	-	-	-	-	-
Female	0.85 (0.78 - 0.91)	**0.89 (0.82 - 0.96)**	1.23 (1.04 - 1.45)	1.12 (0.94 - 1.33)	0.05 (-0.06 - 0.15)	0.00 (-0.11 - 1.11)	0.95 (0.81 - 1.11)	0.96 (0.81 - 1.13)
Social Deprivation								
IMD 1-3	-	-	-	-	-	-	-	-
IMD 4-5	0.99 (0.91 - 1.08)	1.01 (0.93 - 1.10)	1.18 (0.99 - 1.41)	1.09 (0.91 - 1.30)	0.14 (0.03 - 0.26)	0.10 (-0.02 - 0.22)	1.33 (1.12 - 1.58)	**1.29 (1.09 - 1.54)**
Smoking status*								
Never	-	-	-	-	-	-	-	-
Ex-smoker	0.95 (0.87 - 1.04)	0.91 (0.82 - 1.01)	0.89 (0.71 - 1.11)	1.06 (0.84 - 1.34)	-0.90 (-0.22 - 0.04)	0.03 (-0.10 - 0.25)	1.16 (0.93 - 1.43)	1.16 (0.93 - 1.46)
Current	0.92 (0.81 - 1.03)	0.93 (0.88 - 1.08)	1.48 (1.12 - 1.95)	**1.42 (1.07 - 1.88)**	0.34 (0.17 - 0.51)	**0.34 (0.16 - 0.51)**	1.26 (0.96 - 1.65)	1.23 (0.94 - 1.63)
Premorbid Depression-anxiety	0.84 (0.76 - 0.93)	**0.87 (0.78 - 0.96)**	1.26 (1.01 - 1.56)	**1.28 (1.02 - 1.60)**	0.09 (-0.06 - 0.23)	0.12 (-0.22 - 0.27)	1.19 (0.96 - 1.46)	1.17 (0.91 - 1.52)
Premorbid IBS	0.64 (0.56 - 0.72)	**0.66 (0.58 - 0.75)**	2.05(1.60 - 2.62)	**1.87 (1.44 - 2.41)**	0.16 (-0.01 – 0.34)	0.08 (-0.10 - 0.25)	1.12 (0.87 - 1.44)	1.18 (0.95 - 1.46)
Era of diagnosis								
Era 1	-	-	-	-	-	-	-	-
Era 2	1.06 (0.95 - 1.18)	1.06 (0.95 - 1.18)	1.08 (0.86 - 1.36)	1.04 (0.82 - 1.32)	-0.06 (-0.21 - 0.08)	-0.74 (-0.22 - 0.07)	1.34 (1.07 - 1.68)	**1.31 (1.04 - 1.64)**
Era 3	1.03 (0.92 - 1.15)	1.01 (0.91 - 1.13)	1.13 (0.89 - 1.42)	1.05 (0.83 - 1.32)	-0.10 (-0.25 - 0.06)	-1.13 (-0.28 - 0.27)	1.62 (1.29 - 2.05)	**1.57 (1.23 - 1.99)**
Era 4	1.02 (0.92 - 1.14)	1.00 (0.89 - 1.12)	0.94 (0.74 - 1.20)	0.88 (0.68 - 1.12)	-0.18 (-0.34 - -0.03)	-0.22 (-0.37 - 0.06)	1.69 (1.34 - 2.12)	**1.61 (1.26 - 2.03)**

Bold indicates statistical significance in adjusted model Note: Multiple regression includes all variables and covariates of simple regression. Abbreviations: CS, Corticosteroids; IM, Immunomodulator; HR, Hazard Ratio; CI, confidence interval; IMD, index of multiple deprivations

IMD categories 4 and 5 [most deprived] vs IMD categories 1, 2 and 3 [least deprived]

Era 1: 2003 – 2005, Era 2 2006 – 2008, Era 3 2009- 2011 and Era 4 2012 – 2016

First CS use: Time to first CS prescription following diagnosis

CS dependency: Corticosteroid dependency defined as a repeat steroid prescription within 3 months of the end of a previous steroid prescription or patients with steroid prescriptions for greater than 3 consecutive months

Hospitalisation: First IBD-related hospital admission following diagnosis

Time to diagnosis: Time from first primary care consultation for gastrointestinal symptom(s)

Consultation intensity: consultation frequency per person in the year prior to IBD diagnosis

Abbreviation gastrointestinal (GI)